EHA 2020 | Combining B-cell receptor antagonists and venetoclax in CLL

Richard Furman, MD, of the Weill Cornell Medical College, New York, NY, outlines the benefit of combining B-cell receptor antagonist and venetoclax to provide a synergistic effect in chronic lymphocytic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).